Compare PHAT & ABX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PHAT | ABX |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | United States | United States |
| Employees | 371 | 326 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 969.8M | 1.1B |
| IPO Year | 2019 | N/A |
| Metric | PHAT | ABX |
|---|---|---|
| Price | $12.47 | $11.19 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | ★ $19.83 | $9.50 |
| AVG Volume (30 Days) | ★ 1.0M | 710.9K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 2.13% |
| EPS Growth | ★ 42.72 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $175,110,000.00 | N/A |
| Revenue This Year | $93.04 | $19.18 |
| Revenue Next Year | $58.91 | $14.60 |
| P/E Ratio | ★ N/A | $74.88 |
| Revenue Growth | ★ 216.93 | N/A |
| 52 Week Low | $7.61 | $7.18 |
| 52 Week High | $18.31 | $12.44 |
| Indicator | PHAT | ABX |
|---|---|---|
| Relative Strength Index (RSI) | 67.90 | 59.60 |
| Support Level | $12.31 | $8.33 |
| Resistance Level | $13.26 | N/A |
| Average True Range (ATR) | 0.60 | 0.59 |
| MACD | 0.23 | 0.13 |
| Stochastic Oscillator | 98.60 | 62.35 |
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Abacus Global Management Inc is a financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. The company operates through four distinct yet complementary divisions: Abacus Life Solutions, Abacus Asset Group, Abacus Intel, and Abacus Wealth Advisors. It operates through three reportable segments, Asset management, Life solutions, and Technology services. It derives the majority revenue from Life solutions segment that generates revenues by buying, selling, and trading policies, and maintaining policies until receipt of death benefits. It also generates revenue by originating life insurance policy settlements between investors or buyers, and the sellers, who is often the original policy owner.